2002-06-12
Safety aspects of HIV-protease inhibitors
Publication
Publication
Veiligheids aspecten van HIV-proteaseremmers
The objectives of this thesis were to provide more insight into the risk and risk factors of adverse drug reactions associated with HIV-protease inhibitor treatment under non-experimental everyday circumstances. By recognition of risk factors, patients at risk can be identified beforehand and risk management can be targeted more efficiently, hence ultimately improving the safety of HIV-protease inhibitor treatment. In the studies presented in this thesis we applied multiple research strategies. tn which the nationwide ATHENA cohort played a central role.
| Additional Metadata | |
|---|---|
| , , , , , , | |
| The publication of this thesis was financially supported by Abbott BV, Boehringer Ingelheim BV, Bristol-Myers Squibb BV, Glaxo Smith Kline BV, Merck Sharp & Dohme BV and Roche Pharmaceuticals BV. | |
| B.H.Ch. Stricker (Bruno) | |
| Erasmus University Rotterdam | |
| hdl.handle.net/1765/31921 | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Dieleman, J. (2002, June 12). Safety aspects of HIV-protease inhibitors. Retrieved from http://hdl.handle.net/1765/31921 |
|
